Covid-19 roundup: Amgen tosses Otezla into anti-inflammatory mix; Trump thickens plot around US probe into virus origin
Following in the footsteps of other large drugmakers who have repurposed their entrenched therapies against Covid-19, Amgen has released another weapon in its arsenal that could play a more immediate role in the pandemic.
Otezla — the blockbuster psoriasis drug Amgen snagged from Celgene in a $13.4 billion deal last year — will enter the clinic “in the coming weeks to be investigated as a potential immunomodulatory treatment in adult patients with the disease,” R&D chief David Reese said in an earnings call.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
